Press Releases

Flagship Pioneering and its portfolio companies make news because of their transformative approaches to solving global challenges. If you have needs beyond these resources, please contact press@flagshippioneering.com.

company

year

domain

New Publication in Cancer Research Highlights Discovery of SY-1365, a First-in-Class Selective CDK7 Inhibitor, and its Promise as a Potentially Transformative Targeted Approach for Difficult-to-Treat Cancers

Syros Pharmaceuticals 05.07.2019

Syros Announces Dose Escalation Data from Phase 1 Trial of SY-1365 Demonstrating Proof-of-Mechanism at Tolerable Doses in Patients with Advanced Solid Tumors

Syros Pharmaceuticals 11.15.2018

Syros Announces Appointment of Michael W. Bonney to Its Board of Directors

Syros Pharmaceuticals 06.14.2018

Syros Announces Appointment of Jeremy P. Springhorn as Chief Business Officer

Syros Pharmaceuticals 11.13.2017

Syros Receives FDA Orphan Drug Designation for SY-1425 for Treatment of AML

Syros Pharmaceuticals 08.21.2017

Syros Announces Publication in Cell Highlighting Gene Control as Important and Rapidly Progressing Area of Research for Yielding New Medicines to Treat Cancer

Syros Pharmaceuticals 02.09.2017

Syros Appoints Industry Leader Peter Wirth as Chair of its Board of Directors

Syros Pharmaceuticals 01.30.2017

Syros Pharmaceuticals Announces Pricing of Initial Public Offering

Syros Pharmaceuticals 06.29.2016

Syros Pharmaceuticals Presents New Data Demonstrating Significant Anti - Tumor Activity of its Selective CDK7 Inhibitor in Preclinical Models of Acute Myeloid Leukemia

Syros Pharmaceuticals 04.20.2016

Syros Pharmaceuticals Presents Data Demonstrating Significant Anti - Cancer Activity of SY - 1425 in Preclinical Models of Acute Myeloid Leukemia

Syros Pharmaceuticals 04.18.2016

Loading